The use ofcombination of LOX and COX specific inhibitors has been described in colon andpancreatic cancer models [47, 48].Recently, Schroeder et al. [49]have reported that treatment of A549 lung cancer cell line and transformed cell1198, derived from BEAS-2B, with a triple combination of clinical relevant concentrationsof celecoxib (COX inhibitor), MK886, and REV 5901 (both LOX inhibitors)resulted in significant suppression of growth and cell death induction in bothcell lines. The gene discussed is LOX; the disease is lung carcinoma.